PFE vs. GSK
Compare and contrast key facts about Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: PFE or GSK.
Correlation
The correlation between PFE and GSK is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
PFE vs. GSK - Performance Comparison
Key characteristics
PFE:
-0.23
GSK:
-0.31
PFE:
-0.18
GSK:
-0.29
PFE:
0.98
GSK:
0.97
PFE:
-0.10
GSK:
-0.27
PFE:
-0.50
GSK:
-0.50
PFE:
10.69%
GSK:
15.38%
PFE:
22.78%
GSK:
24.69%
PFE:
-54.82%
GSK:
-55.21%
PFE:
-53.05%
GSK:
-15.14%
Fundamentals
PFE:
$140.08B
GSK:
$76.49B
PFE:
$1.41
GSK:
$1.61
PFE:
17.52
GSK:
23.38
PFE:
0.59
GSK:
0.37
PFE:
$48.75B
GSK:
$24.01B
PFE:
$31.22B
GSK:
$16.98B
PFE:
$12.18B
GSK:
$5.14B
Returns By Period
In the year-to-date period, PFE achieves a -5.36% return, which is significantly lower than GSK's 12.52% return. Over the past 10 years, PFE has underperformed GSK with an annualized return of 1.27%, while GSK has yielded a comparatively higher 2.66% annualized return.
PFE
-5.36%
-5.90%
-10.88%
-4.73%
-0.69%
1.27%
GSK
12.52%
-0.82%
-2.44%
-6.26%
4.48%
2.66%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
PFE vs. GSK — Risk-Adjusted Performance Rank
PFE
GSK
PFE vs. GSK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
PFE vs. GSK - Dividend Comparison
PFE's dividend yield for the trailing twelve months is around 6.84%, more than GSK's 4.12% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PFE Pfizer Inc. | 6.84% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.54% | 3.70% | 3.48% | 3.34% |
GSK GlaxoSmithKline plc | 4.12% | 4.60% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% |
Drawdowns
PFE vs. GSK - Drawdown Comparison
The maximum PFE drawdown since its inception was -54.82%, roughly equal to the maximum GSK drawdown of -55.21%. Use the drawdown chart below to compare losses from any high point for PFE and GSK. For additional features, visit the drawdowns tool.
Volatility
PFE vs. GSK - Volatility Comparison
Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK) have volatilities of 6.03% and 5.83%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Financials
PFE vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Pfizer Inc. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities